The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).
 
Dimitrios Makrakis
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Vadim S Koshkin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen; Pfizer/EMD Serono; Seattle Genetics/Astellas
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Clovis Oncology; Endocyte; Nektar
Travel, Accommodations, Expenses - AstraZeneca; Janssen
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Incyte (Inst); Nektar (Inst); Peleton (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Tyler Francis Stewart
Consulting or Advisory Role - Seattle Genetics/Astellas
 
Victor Sacristan Santos
No Relationships to Disclose
 
Jayanshu Jain
No Relationships to Disclose
 
Rafael Morales-Barrera
Consulting or Advisory Role - AstraZeneca; MSD; Sanofi
Speakers' Bureau - Asofarma; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Johnson & Johnson; Lilly; MSD; Roche/Genentech; Sanofi
 
Michael E. Devitt
Consulting or Advisory Role - Bayer
 
Lucia Carril-Ajuria
No Relationships to Disclose
 
Ariel Ann Nelson
No Relationships to Disclose
 
Alexander Sankin
No Relationships to Disclose
 
Roubini Zakopoulou
No Relationships to Disclose
 
David James Pinato
Consulting or Advisory Role - Eisai; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb; MSD Oncology
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb
 
Ana Fröbe
No Relationships to Disclose
 
Monika Joshi
No Relationships to Disclose
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Pfizer; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Janssen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; QED Therapeutics
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Pfizer (Inst); QED Therapeutics (Inst)
 
Ali Raza Khaki
Stock and Other Ownership Interests - Merck; Sanofi